前癌消对前列腺癌雄激素受体共调节因子的影响
|
摘要
研究背景
前列腺癌是欧美国家老年男性最常见的恶性肿瘤,我国一直被认为是前列腺癌的低发地区,但近几十年来随着人们生活条件提高和生活方式的改变,我国前列腺癌发病率呈明显上升趋势。前列腺癌可分为雄激素依赖型和雄激素非依赖型两种类型。早期雄激素依赖型前列腺癌对雄激素阻断治疗比较敏感,但大多数患者在经历12-18个月雄激素阻断治疗后,雄激素依赖型前列腺癌会转变为雄激素非依赖型前列腺癌,此时对抗雄激素治疗不再有效,也无其他较好治疗方法,最终导致患者死亡。
中医治疗癌症,源远流长,方法众多,疗效可靠,潜力巨大。具有补肾祛瘀功效的中药复方“前癌消”在临床治疗前列腺癌取得了较好的疗效。本课题组前期对该方的动物实验研究已证实前癌消可以延缓前列腺癌从雄激素依赖向雄激素非依赖的转化且对已进展到雄激素非依赖阶段的前列腺癌病变有较好的控制作用；同时也提示了在前列腺癌雄激素依赖阶段该方可能具有性激素样作用,应当慎用。前期体外细胞实验结果表明,前癌消对激素依赖性前列腺癌细胞可能有一定的促进生长作用,而与雄激素剥夺治疗联合使用,可加强雄激素剥夺治疗对于前列腺癌细胞生长的抑制作用。
近年来的研究表明,雄激素受体(AR)活性的异常与雄激素非依赖性前列腺癌的发生关系密切。前列腺癌细胞中AR共调节因子的异常是导致AR异常活性的关键因素之一本实验目的：观察前癌消对裸鼠前列腺癌瘤组织及人雄激素依赖细胞系LNCaP细胞雄激素受体及其共调节因子的表达,以探讨前癌消治疗前列腺癌的相关分子机制。方法
首先进行人雄激素依赖细胞系LNCaP细胞培养,培养成功后将该细胞与基质胶的1：1混合物接种到裸鼠皮下,制备前列腺癌动物模型。造模成功后,当裸鼠肿瘤长至450mm3左右时,随机分为模型组、单纯中药组、单纯去势组、去势加中药组四组。单纯去势组、去势加中药组行去势手术摘除睾丸,然后给予单纯去势组生理盐水灌胃,去势加中药组前癌消水煎剂灌胃,同时模型组、单纯中药组分别灌胃生理盐水和前癌消水煎剂；以上灌胃四周后处死动物,摘取瘤组织称重并做石蜡包埋切片,银染技术检测瘤细胞中核仁组成区嗜银蛋白AgNOR表达量的变化,免疫组织化学染色观察瘤组织AR共调节因子SRC-1、NCoR的表达情况。
将40只雄性Wistar大鼠随机分为对照组、单纯给药组、单纯去势组和去势给药组,对去势组行去势手术摘除双侧睾丸。术后一周,给药组以临床等效剂量前癌消水煎剂灌胃,不给药组以生理盐水灌胃,共3天后,行腹主动脉采血,获得4组不同的含药血清：对照组、单纯给药组、单纯去势组和去势给药组。用各组大鼠血清对对数生长期人雄激素依赖细胞系LNCaP细胞实施干预,48小时后检测：细胞增殖和凋亡相关因子：K i67.Bax、 Bc12mRNA的表达(荧光定量RT-PCR); AR基因与蛋白表达(荧光定量RT-PCR, Westernblot);雄激素受体共调节因子SRC-l,NCoR的表达(荧光定量RT-PCR)。结果
1.前癌消对裸鼠前列腺癌组织中瘤细胞核仁组成区嗜银蛋白AgNOR表达的影响
核仁组成区嗜银蛋白AgNOR颗粒呈黑棕色颗粒,分布于核内,颗粒形态呈聚集型弥漫型；模型组AgNOR颗粒表达最多,单纯中药组AgNOR表达比模型组少(P<0.01),单纯去势组AgNOR表达比模型组少(P<0.01),去势加中药组AgNOR表达比单纯去势组少(P<0.01)。
2.前癌消对裸鼠前列腺癌组织中AR共调节因子SRC-1、 NCoR表达的影响
SRC-1在模型组、单纯给药组、去势给药组、单纯去势组均有表达。单纯去势组(雄激素非依赖性前列腺癌)和模型组(雄激素依赖性前列腺癌)相比,SRC-1表达明显增加(p<0.01)；单纯给药组和模型组相比,SRC-1表达明显减少(P<0.01)；去势给药组与单纯去势组相比SRC-1表达也明显减少(P<0.01),说明前癌消可能是通过降低前列腺癌细胞SRC-1蛋白的表达水平,从而降低AR的转录活性,延缓前列腺癌雄激素非依赖性的转变过程。
NCoR在模型组、单纯给药组、去势给药组均有表达,而单纯去势组(雄激素非依赖性前列腺癌)无明显表达。单纯去势组和模型组相比,NCoR表达明显减少(p<0.01)；单纯给药组和模型组相比,NCoR表达明显增加(P<0.01)；去势给药组与单纯去势组相比NCoR表达也明显增加(P<0.01),提示前癌消可能通过升高NcoR蛋白表达水平从而延缓前列腺癌雄激素非依赖性的转变过程。
3.前癌消对LNCaP细胞增殖和凋亡相关因子的影响
四组细胞模型增殖因子Ki67mRNA以及凋亡相关因子Bax、 Bcl-2mRNA的表达水平的荧光定量PCR的结果显示：单纯给药组Ki67mRNA的表达大于对照组(P<0.05),单纯去势组Ki67mRNA的表达小于对照组(P<0.05),去势给药组Ki67mRNA的表达小于单纯去势组(P<0.05)。四组细胞模型BaxmRNA的表达水平不具有统计学意义(P>0.05)。单纯给药组Bcl-2mRNA的表达大于对照组(P<0.05),单纯去势组Bcl-2mRNA的表达小于对照组(P<0.05),去势给药组Bcl-2mRNA的表达小于单纯去势组(P<0.05)。
4.前癌消对LNCaP细胞AR基因与蛋白表达的影响
四组细胞模型AR表达western-blot的结果显示：单纯给药组AR的表达大于对照组(P<0.05),单纯去势组AR的表达小于对照组(P<0.05),去势给药组AR的表达小于单纯去势组(P<0.05)。四组细胞模型ARmRNA表达荧光定量PCR的结果显示：单纯给药组ARmRNA的表达大于对照组(P<0.05),单纯去势组ARmRNA的表达小于对照组(P<0.05),去势给药组ARmRNA的表达小于单纯去势组(P<0.05)。
5.前癌消对LNCaP细胞AR共调节因子SRC-1、 NCORmRNA表达的影响
单纯给药组SRC-lmRNA的表达大于对照组(P<0.05),单纯去势组SRC-lmRNA的表达小于对照组(P<0.05),去势给药组SRC-lmRNA的表达小于单纯去势组(P＜O.05)。
单纯给药组NCoRmRNA的表达小于对照组(P<0.05),单纯去势组NCoRmRNA的表达大于对照组(P<0.05),去势给药组NCoRmRNA的表达大于单纯去势组(P<0.05)。
结论：
前癌消对未经去势治疗的前列腺癌细胞具有一定促进增殖作用,这可能与其含有补肾中药的性激素样作用有关,需要进一步研究；前癌消可抑制去势后前列腺癌细胞的AR表达,并可减少AR共刺激因子SRC-1的表达而增加AR共抑制因子NCoR的表达,从而降低AR的转录活性,抑制AR介导的前列腺癌细胞的增殖,且通过抑制Bcl-2的表达而影响前列腺癌细胞的凋亡。这可能是前癌消延缓前列腺癌从雄激素依赖到非依赖转化以治疗前列腺癌的机制之一。
Objective
Prostate cancer is the most common malignant tumor of the older men in the United States and Europe, our country has always been considered a low-incidence area of prostate cancer, however, as the living conditions and lifestyle changes, the incidence of prostate cancer showed a increasing trend year after year in China and the patient is also gradually getting younger and younger. Prostate cancer can be divided into two typesof androgen-dependent prostate cancer and androgen-independent prostate cancer. Early androgen-dependent prostate cancer is more sensitive to androgen deprivation therapy, However,after a period of12to18months,nearly all patients under the treatment of hormone deprivation therapies are progressing into androgen-dependent prostate cancer.Hormone therapy introduce no therapeutic actions in this stage, neither other therapies. A rapid progression can be observed in this stage and most patients stride to the end of the life.
Chinese medicine performs well in the clinical practice in treating different Kinds of cancers and it is more and more employed in cancer treatment these years for the advantages of little side effect, multi-targets and multi functioning levels, focusing on comprehensive regulation of the body compared to the modern therapies.The QAX created by prof. Pei Wang,who is a Chinese oncologists,on the basis of his experiences in treating cancers, which is called the QAX with the function of nourishing the kidney and promoting blood circulation, The previous research in our laboratory indicated that the QAX should be used with cautions during the stage of androgen-dependent prostate cancer and it will give good performance on treating the disease during the androgen-independent stage.Besides, it can delay the disease progression from androgen-dependent stage into the androgen-independent.LNCaP cells, the classic androgen-dependent prostate cancer cells, are used in our program to test the effects of the QAX above in vitro, and We will further study on the basis of preliminary in vivo experiments to discuss the molecular mechanism of prostate cancer and to provide more theoretical basis for further clinical application.
Methods
First, human androgen dependent cell line LNCaP cell was cultured.The cells with the1:1mixture of matrigel was inoculated in nude mice, preparing animal models of prostate cancer. After the modeling, nude mice bearing prostate cancer is the study objective and the QAX is intervening factors.When the tumor in nude mice grew to about45Omm3, randomly divided into the normal control group, the QAX group, the castration group and the castration+QAX group, the normal control group and the castration group were given saline after the castration, the QAX group and the castration+QAX group were given the QAX.
Four weeks after the QAX intervention, all animals were sacrificed and removal of the tumor.Immunohistochemistry staining tumor for SRC-1and NCOR expression in tumor tissue. Using factors related to proliferation label AgNOR,examine it expressing characteristic in four groups.The methods of intragastric administration of equivalent dose decoction and surgical removal of the testicles were employed to prepare4groups of different rat serums, the Normal Control group, the QAX group, the Castration group and the Castration+QAX group. The serums described above are used to interfere the human androgen-dependent prostate cancer LNCaP cells to examine ARmRNA and protein (quantitative real time RT-PCR, Western blot), factors related to proliferation label Ki67and factors related to apoptosis label BCL-2、 Bax (quantitative real time RT-PCR), steroid receptor coactivator-l(SRC-l),nuclear receptor corepressors(NCOR)(quantitative real time RT-PCR).
Results
1. Using immunohistochemistry technique labeling SRC-1、 NCOR,study expressing characteristic of them in four groups of tumor tissue.the Normal Control group, the QAX group, the Castration group and the Castration+QAX group.
Regarding expression of AR, it shows that high expression in tumor cells of the Castration group, AR in the Normal Control group is less than the Castration group:AR expression in the QAX group was less than the Normal Control group, AR in the Castration+QAX group was less than the QAX group.
AR in the Castration group is less than the Castration+QAX group; AR expression in the Normal Control group was less than the QAX group.
2. Using factors related to proliferation label AgNOR,examine it expressing characteristic in four groups
high expression in tumor cells of the Normal Control group, AR in the QAX group is less than the Normal Control group the Castration+QAX group:AR expression in the Castration group was less than the Castration+QAX group.
3. ARmRNA and protein
ARmRNA and protein in the Normal Control group was less than the QAX group; AR expression in than the Castration+QAX group was less the Castration group.
4. factors related to proliferation label Ki67and factors related to apoptosis label BCL-2、 Bax
Ki67and BCL-2in the QAX group is less than the Normal Control group the Castration+QAX group:Ki67and BCL-2expression in the Castration group was less than the Castration+QAX group.
5. Steroid receptor coactivator-1(SRC-1), nuclear receptor corepressors(NCOR)
SRC-1in the QAX group was less than the Normal Control group the Castration+QAX group:SRC-1expression in the Castration group was less than the Castration+QAX group.
SRC-1in the QAX group was more than the Normal Control group the Castration+QAX group:SRC-1expression in the Castration group was more than the Castration+QAX group.
Conclusion
1. The QAX with the function of nourishing the kidnedy and Promoting blood circulation can reduce the SRC-1. AgNOR expression of the tumor tissue of the nude mice.
2. The QAX with the function of nourishing the kidnedy and Promoting blood circulation can promote the AR、Ki67mRNA、 SRC-1mRNA、 Bcl-2mRNA,and reduce expression of NCORmRNA expression of LNCaP cells.
3. Castration can suppress the AR mRNA and protein、 Ki67mRNA SRC-lmRNA、 Bcl-2mRNA expression of LNCaP cells, and promote the expression of NCOR mRNA.
4. AR mRNA and protein、 Ki67mRNA、 SRC-lmRNA、 Bcl-2mRNA expression in the Castration and the QAX group was less than in the Castration group.
前列腺癌是欧美国家老年男性最常见的恶性肿瘤,我国一直被认为是前列腺癌的低发地区,但近几十年来随着人们生活条件提高和生活方式的改变,我国前列腺癌发病率呈明显上升趋势。前列腺癌可分为雄激素依赖型和雄激素非依赖型两种类型。早期雄激素依赖型前列腺癌对雄激素阻断治疗比较敏感,但大多数患者在经历12-18个月雄激素阻断治疗后,雄激素依赖型前列腺癌会转变为雄激素非依赖型前列腺癌,此时对抗雄激素治疗不再有效,也无其他较好治疗方法,最终导致患者死亡。
中医治疗癌症,源远流长,方法众多,疗效可靠,潜力巨大。具有补肾祛瘀功效的中药复方“前癌消”在临床治疗前列腺癌取得了较好的疗效。本课题组前期对该方的动物实验研究已证实前癌消可以延缓前列腺癌从雄激素依赖向雄激素非依赖的转化且对已进展到雄激素非依赖阶段的前列腺癌病变有较好的控制作用；同时也提示了在前列腺癌雄激素依赖阶段该方可能具有性激素样作用,应当慎用。前期体外细胞实验结果表明,前癌消对激素依赖性前列腺癌细胞可能有一定的促进生长作用,而与雄激素剥夺治疗联合使用,可加强雄激素剥夺治疗对于前列腺癌细胞生长的抑制作用。
近年来的研究表明,雄激素受体(AR)活性的异常与雄激素非依赖性前列腺癌的发生关系密切。前列腺癌细胞中AR共调节因子的异常是导致AR异常活性的关键因素之一本实验目的：观察前癌消对裸鼠前列腺癌瘤组织及人雄激素依赖细胞系LNCaP细胞雄激素受体及其共调节因子的表达,以探讨前癌消治疗前列腺癌的相关分子机制。方法
首先进行人雄激素依赖细胞系LNCaP细胞培养,培养成功后将该细胞与基质胶的1：1混合物接种到裸鼠皮下,制备前列腺癌动物模型。造模成功后,当裸鼠肿瘤长至450mm3左右时,随机分为模型组、单纯中药组、单纯去势组、去势加中药组四组。单纯去势组、去势加中药组行去势手术摘除睾丸,然后给予单纯去势组生理盐水灌胃,去势加中药组前癌消水煎剂灌胃,同时模型组、单纯中药组分别灌胃生理盐水和前癌消水煎剂；以上灌胃四周后处死动物,摘取瘤组织称重并做石蜡包埋切片,银染技术检测瘤细胞中核仁组成区嗜银蛋白AgNOR表达量的变化,免疫组织化学染色观察瘤组织AR共调节因子SRC-1、NCoR的表达情况。
将40只雄性Wistar大鼠随机分为对照组、单纯给药组、单纯去势组和去势给药组,对去势组行去势手术摘除双侧睾丸。术后一周,给药组以临床等效剂量前癌消水煎剂灌胃,不给药组以生理盐水灌胃,共3天后,行腹主动脉采血,获得4组不同的含药血清：对照组、单纯给药组、单纯去势组和去势给药组。用各组大鼠血清对对数生长期人雄激素依赖细胞系LNCaP细胞实施干预,48小时后检测：细胞增殖和凋亡相关因子：K i67.Bax、 Bc12mRNA的表达(荧光定量RT-PCR); AR基因与蛋白表达(荧光定量RT-PCR, Westernblot);雄激素受体共调节因子SRC-l,NCoR的表达(荧光定量RT-PCR)。结果
1.前癌消对裸鼠前列腺癌组织中瘤细胞核仁组成区嗜银蛋白AgNOR表达的影响
核仁组成区嗜银蛋白AgNOR颗粒呈黑棕色颗粒,分布于核内,颗粒形态呈聚集型弥漫型；模型组AgNOR颗粒表达最多,单纯中药组AgNOR表达比模型组少(P<0.01),单纯去势组AgNOR表达比模型组少(P<0.01),去势加中药组AgNOR表达比单纯去势组少(P<0.01)。
2.前癌消对裸鼠前列腺癌组织中AR共调节因子SRC-1、 NCoR表达的影响
SRC-1在模型组、单纯给药组、去势给药组、单纯去势组均有表达。单纯去势组(雄激素非依赖性前列腺癌)和模型组(雄激素依赖性前列腺癌)相比,SRC-1表达明显增加(p<0.01)；单纯给药组和模型组相比,SRC-1表达明显减少(P<0.01)；去势给药组与单纯去势组相比SRC-1表达也明显减少(P<0.01),说明前癌消可能是通过降低前列腺癌细胞SRC-1蛋白的表达水平,从而降低AR的转录活性,延缓前列腺癌雄激素非依赖性的转变过程。
NCoR在模型组、单纯给药组、去势给药组均有表达,而单纯去势组(雄激素非依赖性前列腺癌)无明显表达。单纯去势组和模型组相比,NCoR表达明显减少(p<0.01)；单纯给药组和模型组相比,NCoR表达明显增加(P<0.01)；去势给药组与单纯去势组相比NCoR表达也明显增加(P<0.01),提示前癌消可能通过升高NcoR蛋白表达水平从而延缓前列腺癌雄激素非依赖性的转变过程。
3.前癌消对LNCaP细胞增殖和凋亡相关因子的影响
四组细胞模型增殖因子Ki67mRNA以及凋亡相关因子Bax、 Bcl-2mRNA的表达水平的荧光定量PCR的结果显示：单纯给药组Ki67mRNA的表达大于对照组(P<0.05),单纯去势组Ki67mRNA的表达小于对照组(P<0.05),去势给药组Ki67mRNA的表达小于单纯去势组(P<0.05)。四组细胞模型BaxmRNA的表达水平不具有统计学意义(P>0.05)。单纯给药组Bcl-2mRNA的表达大于对照组(P<0.05),单纯去势组Bcl-2mRNA的表达小于对照组(P<0.05),去势给药组Bcl-2mRNA的表达小于单纯去势组(P<0.05)。
4.前癌消对LNCaP细胞AR基因与蛋白表达的影响
四组细胞模型AR表达western-blot的结果显示：单纯给药组AR的表达大于对照组(P<0.05),单纯去势组AR的表达小于对照组(P<0.05),去势给药组AR的表达小于单纯去势组(P<0.05)。四组细胞模型ARmRNA表达荧光定量PCR的结果显示：单纯给药组ARmRNA的表达大于对照组(P<0.05),单纯去势组ARmRNA的表达小于对照组(P<0.05),去势给药组ARmRNA的表达小于单纯去势组(P<0.05)。
5.前癌消对LNCaP细胞AR共调节因子SRC-1、 NCORmRNA表达的影响
单纯给药组SRC-lmRNA的表达大于对照组(P<0.05),单纯去势组SRC-lmRNA的表达小于对照组(P<0.05),去势给药组SRC-lmRNA的表达小于单纯去势组(P＜O.05)。
单纯给药组NCoRmRNA的表达小于对照组(P<0.05),单纯去势组NCoRmRNA的表达大于对照组(P<0.05),去势给药组NCoRmRNA的表达大于单纯去势组(P<0.05)。
结论：
前癌消对未经去势治疗的前列腺癌细胞具有一定促进增殖作用,这可能与其含有补肾中药的性激素样作用有关,需要进一步研究；前癌消可抑制去势后前列腺癌细胞的AR表达,并可减少AR共刺激因子SRC-1的表达而增加AR共抑制因子NCoR的表达,从而降低AR的转录活性,抑制AR介导的前列腺癌细胞的增殖,且通过抑制Bcl-2的表达而影响前列腺癌细胞的凋亡。这可能是前癌消延缓前列腺癌从雄激素依赖到非依赖转化以治疗前列腺癌的机制之一。
Objective
Prostate cancer is the most common malignant tumor of the older men in the United States and Europe, our country has always been considered a low-incidence area of prostate cancer, however, as the living conditions and lifestyle changes, the incidence of prostate cancer showed a increasing trend year after year in China and the patient is also gradually getting younger and younger. Prostate cancer can be divided into two typesof androgen-dependent prostate cancer and androgen-independent prostate cancer. Early androgen-dependent prostate cancer is more sensitive to androgen deprivation therapy, However,after a period of12to18months,nearly all patients under the treatment of hormone deprivation therapies are progressing into androgen-dependent prostate cancer.Hormone therapy introduce no therapeutic actions in this stage, neither other therapies. A rapid progression can be observed in this stage and most patients stride to the end of the life.
Chinese medicine performs well in the clinical practice in treating different Kinds of cancers and it is more and more employed in cancer treatment these years for the advantages of little side effect, multi-targets and multi functioning levels, focusing on comprehensive regulation of the body compared to the modern therapies.The QAX created by prof. Pei Wang,who is a Chinese oncologists,on the basis of his experiences in treating cancers, which is called the QAX with the function of nourishing the kidney and promoting blood circulation, The previous research in our laboratory indicated that the QAX should be used with cautions during the stage of androgen-dependent prostate cancer and it will give good performance on treating the disease during the androgen-independent stage.Besides, it can delay the disease progression from androgen-dependent stage into the androgen-independent.LNCaP cells, the classic androgen-dependent prostate cancer cells, are used in our program to test the effects of the QAX above in vitro, and We will further study on the basis of preliminary in vivo experiments to discuss the molecular mechanism of prostate cancer and to provide more theoretical basis for further clinical application.
Methods
First, human androgen dependent cell line LNCaP cell was cultured.The cells with the1:1mixture of matrigel was inoculated in nude mice, preparing animal models of prostate cancer. After the modeling, nude mice bearing prostate cancer is the study objective and the QAX is intervening factors.When the tumor in nude mice grew to about45Omm3, randomly divided into the normal control group, the QAX group, the castration group and the castration+QAX group, the normal control group and the castration group were given saline after the castration, the QAX group and the castration+QAX group were given the QAX.
Four weeks after the QAX intervention, all animals were sacrificed and removal of the tumor.Immunohistochemistry staining tumor for SRC-1and NCOR expression in tumor tissue. Using factors related to proliferation label AgNOR,examine it expressing characteristic in four groups.The methods of intragastric administration of equivalent dose decoction and surgical removal of the testicles were employed to prepare4groups of different rat serums, the Normal Control group, the QAX group, the Castration group and the Castration+QAX group. The serums described above are used to interfere the human androgen-dependent prostate cancer LNCaP cells to examine ARmRNA and protein (quantitative real time RT-PCR, Western blot), factors related to proliferation label Ki67and factors related to apoptosis label BCL-2、 Bax (quantitative real time RT-PCR), steroid receptor coactivator-l(SRC-l),nuclear receptor corepressors(NCOR)(quantitative real time RT-PCR).
Results
1. Using immunohistochemistry technique labeling SRC-1、 NCOR,study expressing characteristic of them in four groups of tumor tissue.the Normal Control group, the QAX group, the Castration group and the Castration+QAX group.
Regarding expression of AR, it shows that high expression in tumor cells of the Castration group, AR in the Normal Control group is less than the Castration group:AR expression in the QAX group was less than the Normal Control group, AR in the Castration+QAX group was less than the QAX group.
AR in the Castration group is less than the Castration+QAX group; AR expression in the Normal Control group was less than the QAX group.
2. Using factors related to proliferation label AgNOR,examine it expressing characteristic in four groups
high expression in tumor cells of the Normal Control group, AR in the QAX group is less than the Normal Control group the Castration+QAX group:AR expression in the Castration group was less than the Castration+QAX group.
3. ARmRNA and protein
ARmRNA and protein in the Normal Control group was less than the QAX group; AR expression in than the Castration+QAX group was less the Castration group.
4. factors related to proliferation label Ki67and factors related to apoptosis label BCL-2、 Bax
Ki67and BCL-2in the QAX group is less than the Normal Control group the Castration+QAX group:Ki67and BCL-2expression in the Castration group was less than the Castration+QAX group.
5. Steroid receptor coactivator-1(SRC-1), nuclear receptor corepressors(NCOR)
SRC-1in the QAX group was less than the Normal Control group the Castration+QAX group:SRC-1expression in the Castration group was less than the Castration+QAX group.
SRC-1in the QAX group was more than the Normal Control group the Castration+QAX group:SRC-1expression in the Castration group was more than the Castration+QAX group.
Conclusion
1. The QAX with the function of nourishing the kidnedy and Promoting blood circulation can reduce the SRC-1. AgNOR expression of the tumor tissue of the nude mice.
2. The QAX with the function of nourishing the kidnedy and Promoting blood circulation can promote the AR、Ki67mRNA、 SRC-1mRNA、 Bcl-2mRNA,and reduce expression of NCORmRNA expression of LNCaP cells.
3. Castration can suppress the AR mRNA and protein、 Ki67mRNA SRC-lmRNA、 Bcl-2mRNA expression of LNCaP cells, and promote the expression of NCOR mRNA.
4. AR mRNA and protein、 Ki67mRNA、 SRC-lmRNA、 Bcl-2mRNA expression in the Castration and the QAX group was less than in the Castration group.
引文
[1]Schrder F H. Early versus delayed endocrine therapy for prostate cancer[J]. Endoc Relat Cancer,2007,14(2):1-11.
[2]Gao X,Loggie B W,Nawaz Z. The roles of sex steroid receptor coregulators in cancer[J]. Mol Cancer,2004,14(5):1-7.
[3]Smith C L,O'Malley B W. Coregulator function:a key to under-standing tissue specificity of selective receptor modulators[J]. Endo Rev,2004,25(6):45-71.
[4]Dehm S M,Tindall D J. Androgen receptor structural and functional elements:role and regulation in prostate cancer[J]. Mol Endocrinol,2007,21(3):2855-2863.
[5]Brinkmann AO. Molecular basis of androgen insensitivity [J]. Mol Cell Endocrinol, 2001,179(9):105-109.
[6]Culig Z,Klocker H,Bartsch G,et al. Androgen receptor in prostate cancer[J]. J Urol,2003, 170(5):1363-1369.
[7]M E Taplin, S P Balk. Androgen receptor:a key molecule in the progression of prostate cancer to hormone independence[J].Journal of Cellular Biochemistry,2004,91(7):483-490.
[8]O.Sartor,Q.Zheng,J.A.Eastham,Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer[J].Urology,1999,53(4):378-380.
[9]E Giovannucci,M J Stampfer,K Krithivas.The CAG repeat within the androgen receptor gene and its relationship to prostate cancer[J].Proceedings of the National Academy of Sciences of the United States of America,1997,94(7):3320-3323.
[10]D O Hardy,H I Scher,T Bogenreider.Androgen receptor CAG repeat lengths in prostate cancer:correlation with age of onset[J].The Journal of Clinical Endocrinology and Metabolism,1996,81(9):4400-4405.
[11]R K Nam,Y Elhaji, M D Krahn.Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression[J].The Journal of Urology,2000, 164(3):567-572.
[12]A Haelens, T Tanner, S Denayer.The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor [J]. Cancer Research, 2007,67(6):4514-4523.
[13]E P Gelmann.Molecular biology of the androgen receptor[J] Journal of Clinical Oncology,2002,20(7):3001-3015.
[14]P J Kallio, J J Palvimo, M Mehto.Analysis of androgen receptor-DNA interactions with receptor proteins produced in insect cells[J].The Journal of Biological Chemistry, 1994,269(4):11514-11522.
[15]CA Berrevoets, A Umar, A O Brinkmann.Antiandrogens:selective androgen receptor modulators [J].Molecular and Cellular Endocrinology,2002,198(3):97-103.
[16]Y Shang, M Myers, M Brown.Formation of the androgen receptor transcription complex [J].Molecular Cell,2002,9(1):601-610.
[17]M.C.Louie,H.Q.Yang,A.H.Ma.Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex [J].Proceedings of the National Academy of Sciences of the United States of America,2003,100(6):2226-2230.
[18]XB Shi,L Xue,J Yang.An androgen-regulated miRNA suppresses Bakl expression and induces androgen-independent growth of prostate cancer cells[J].Proceedings of the National Academy of Sciences of the United States of America,2007,104(3):19983-19988.
[19]C.A.Berrevoets, A.Umar, A O Brinkmann. Antiandrogens:selective androgen receptor modulators [J].Molecular and Cellular Endocrinology,2002,198(7):97-103.
[20]Edwards J,Krishna N S,Grigor K M,et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer[J]. Br J Cancer,2003,89(4):552-526.
[21]Culig Z,Hobisch A,Cronauer M V,et al. Regulation of prostatic growth and function by peptide growth factors[J]. Prostate,1996,28(2):392-405.
[22]Tan J,Sharief Y,Hamil K G,et al. Dehydroepiandrosterone acti-vates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells[J]. Mol Endocrinol,1997,11(4):450-459.
[23]Park J J,Irvine R A,Buchanan G,et al. Breast cancer susceptibility gene l(BRCAl)is a coactivator of the androgen receptor[J]. Cancer Res,2000,60(6):5946.
[24]Gao X,Loggie B W,Nawaz Z. The roles of sex steroid receptor coregulators in cancer[J]. Mol Cancer,2004,14(4):1-7.
[25]Smith C L,O'Malley B W. Coregulator function:a key to under-standing tissue specificity of selective receptor modulators[J]. Endo Rev,2004,25(4):45-71.
[26]Fu M,Rao M,Wang C,et al.Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth[J].Mol Cell Biol,2003,23(3):8563-8575.
[27]Berrevoets P, Doesburg K, Steketee J, et al.Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2(transcriptional intermediary factor) [J]. Mol Endocrinol, 1998,12(3):1172-1183.
[28]Wang G,Liu XM,Kreis W,et al.Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity[J].Biochem Biophys Res Commun,1999,259(4):21-28.
[29]Xu W,Cho H,Evans RM,et al.Acetylation and methylation in nuclear receptor gene activation[J].Methods Enzymol,2003,364(2):205-212.
[30]Culig Z,Klocker H,Bartsch G,et al.Androgen receptor mutations in carcinoma of the prostate:significance for endocrine therapy[J].Am J Pharmacogenomics,2001,1(6):241-9.
[31]Gao X,Loggie B W,Nawaz Z. The roles of sex steroid receptor coregulators in cancer[J]. Mol Cancer,2004,14(5):1-7.
[32]Smith C L,O'Malley B W. Coregulator function:a key to understanding tissue specificity of selective receptor modulators[J]. Endo Rev,2004,25(5):45-71.
[33]Chang C Y,McDonnell D P. Androgen-receptor-cofactor interactions as targets for drug discovery[J]. Trends Pharmacol Sci,2005,26(1):225-228.
[34]Xu J,Qiu Y,DeMayo F J,et al. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1)gene[J]. Science,1998,279(7):1922-1925.
[35]Tanaka Y,Naruse I,Hongo T,et al. Extensive brain hemorrhage and embryonic lethality in a mouse null mutant of CREB-binding protein[J]. Mech Dev,2000,95(6):133-145.
[36]Yao T P,Oh S P,Fuchs M,et al. Gene-dosage dependent embry-onic development and proliferation defects in mice lacking the transcriptional integrator p300[J]. Cell, 1998,93(4):361-372.
[37]Heemers H V,Tindall D J. Androgen receptor(AR)coregulators:a diversity of functions converging on and regulating the AR transcriptional complex[J]. Endo Rev,2007,28(2):778-808.
[38]Chen H,Lin R J,Schiltz R L,et al.Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300[J]. Cell,1997,90(3):569-580.
[39]Stallcup M R,Kim J H,Teyssier C,et al.The roles of protein-protein interactions and protein methylation in transcriptional acti-vation by nuclear receptors and their coactivators. Steroid Biochem[J]. Mol Biol,2003,85(2-5):139-145.
[40]Chen C D,Welsbie D S,Tran C,et al.Molecular determinants of resistance to antiandrogen therapy[J].NatMed,2004,10(5):33-39.
[41]Gregory C W,He B,Johnson R T,et al.A mechanism for andro-gen receptor-mediated prostate cancer recurrence after androgen de-privation therapy [J]. Cancer Res,2001, 61(3):4315-4319.
[42]Zhou H J, Yan J, Luo W,et al.SRC-3 is required for prostate cancer cell proliferation and survival[J].CancerRes,2005,65(7):7976-7983.
[43]Chen H,Lin RJ,Schiltz RL,et al.Nuclear receptor co-activator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with p/CAF and CBPIp300[J].Cell,1997,90(6):569-580.
[44]Li H,Gomes PJ,Chen JD,et al.AC3,a steroid/nuclear receptor associated coactivator that is related to SRC-1 and TIF2[J].Proc Nat/Acad Sci,1997,94(4):6479-8464.
[45]Takeshita A, Cardona GR, Koibuchi N, et val.a novel 1 BO-kDa thvroid hormone receotor activator molecule:exhibits distinct pioperties from steroid receptor co-activator-1[J].J Biol Chem,1997,272(5):27629-27634.
[46]Taneja S S,Ha S,Swenson N K,et al.ART-27,an androgen re-ceptor coactivator regulated in prostate development and cancer[J].J Biol Chem,2004,279(14):13944-13952.
[47]Yeh S, Chang C.Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells [J].Proc Natl Acad Sci USA,1996,93(9):5517-5521.
[48]Sampson ER, Yeh SY, Chang HC, et al.Identification and characterization of androgen receptor associated coregulators in prostate cancer cells[J].J Biol Regul Homeost Agents,2001,15(8):123-129.
[49]Wang Xin,Yang Yue,Guo Xiaojian,et al.Suppression of androgen receptor transactivation by Pyk2 via interaction and phosphorylation of the ARA55 coregulator[J]J Biol Chem,2002,277(7):15426-15431.
[50]Kang HY,Yeh S,Fujimoto N,et al.Cloning and characterization of human prostate coactivator ARA54,a novel protein that associates with the androgen receptor[J].J Biol Chem,1999,274(3):8570-8576.
[51]Hsiao PW,Lin DL,Nakao R,et al.The linkage of Kennedy's neuron disease to ARA24,the first identified androgen receptor polyglutamine region-associated coactivator[J].J Biol Chem,1999,274(2):20229-20234.
[52]Yeh S,Sampson ER,Lee DK,et al.Functional analysis of androgen receptor N-terminal and ligand binding domain interacting coregulators in prostate cancer[J].J Formos Med Assoc,2000,99(6):885-894.
[53]Hsiao PW,Chang C.Isolation and characterization of ARA160 as the first androgen receptor N-terminal-associated coactivator in human prostate cells[J]J Biol Chem,1999,274(5):22373-22379.
[54]Miyamoto H,Rahman M M,Chang C.Molecular basis for the antiandrogen withdrawal syndrome[J].J Cell Biochem,2004,91(1):3-12.
[55]Huang ZhiQing, Li Jiwen, Wong Jiemin, et al.AR possesses an intrinsic hormone-independent transcriptional activity[J].Mol-Endocrinol,2002,16(4):924-3733.
[56]Heinzel T, Lavinsky RM, Mullen TM, et al.A complex containig N-CoR, mSin3 and histone deacetylase mediates transcriptional repression[J].Nature,1997,387(7):43-48.
[57]Cheng S,Brzostek S,Lee SR,et al.Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor[J].Mol-Endocrinol,2002,16(4):1492-1501.
[58]Guoqing Liao,LiuhYow Chen,Aihua Zhang,et al.Regulation of Androgen Receptor Activity by the Nuclear Receptor Corepressor SMRT[J].J Biol Chem,2003,278(2):5052-5061.
[59]Hu X, Lazar MA.The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors[J].Nature,1999,402(5):93-96.
[60]Perissi V,Staszewski LM,McInerney EM,et al.Molecular of nuclear determinants receptor corepressor interaction[J].Genes Dev,1999,13(8):3198-3208.
[61]Nagy L,Kao HY,Love JD,et al.Mechanism of corepressor binding and release from nuclear hormone receptors[J].Genes Dev,1999,13(4):3209-3216.
[62]Xu HE, Stanley TB, Montana VG,et al.Structural basis for antagonist mediated recruitment of nuclear co-repressors by PPARalpha[J].Nature,2002,415(1):813-817.
[63]Ghosh JC,Yang X,Zhang A,et al.Interactions that determine the assembly of a retinoid X receptor/corepressor complex[J].Proc Natl Acad Sci,2002 99(7):5842-5847.
[64]Dotzlaw Helmut, Moehren Udo, Mink Sigrun, et al.Theamino terminus of the human AR is target for corepressor action and antihormone agonism [J]. Mol-Endocrinol, 2002,16(3):661-673.
[65]Fujimoto N,Mizokami A,Harada S,et al.Different expression of androgen receptor coactivators in human prostate[J].Urology,2001,58(9):289-294.
[66]Gregory CW,He B,Johnson RT,et al.A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy [J]. Cancer Res,2001, 61(7):4315-4319.
[67]Osborne CK,Bardou V,Hopp TA,et al.Role of the estrogen receptor coactivator AIBl(SRC-3)and HER-2/neu in tamoxifen resistance in breast cancer[J]J Natl Cancer Inst,2003,95(7):353-361.
[1]史轶蘩主编.协和内分泌和代谢学.北京.科学技术出版社[M].1999：52
[2]白晓霞.植物雌激素与传统的激素替代疗法[J].国外医学妇幼保健分册,2002,13(3)：113-115
[3]Zava DT,Duwe GEstrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro[J].Nutr Cancer,1997,27(1):31-40.
[4]贺红莉,金焕,王继峰,等.雌激素受体调节剂及其相关中药的研究进展[J].中国中药杂志,2002,27(11)：805-807.
[5]Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women; principal resuts From the Women, Health Initiative randomized controlled trial[J].JAMA,2002,288(3);321-333
[6]Albright F. Postmenopausal Osteoporosis[J]. Traps Assoc Amphysic,71940,55(7); 298
[7]孔令娜,左萍萍,植物雌激素研究进展[J].生殖医学杂志,2003,12(1)；46-53
[8]Sakamoto T,Horiguchi H,Oguma E,et al.Effects of diverse dietary phytoestrogens on cell growth,cell cycle and apoptosis in estrogen-receptor-positive breast cancer cells[J].Nutr Biochem,2010,21 (9):856-864.
[9]Lamartiniere CA. Protection against breast cancerwith genistein:acomponent of soy[J].Am J Clin Nutr,2000,717(2):1705-1707.
[10]Galluzzo P, Martini C, Bulzomi P, et al.Quercetin-induced apoptotic cascade in cancer cells:antioxidant versus estrogen receptor alpha-dependent mechanisms[J].Mol Nutr Food Res> 2009,53 (6):699-708.
[11]Mori H, Niwa K, Zheng Q, et al.Cell proliferation in cancer prevention;effects of preventive agents on estrogen-related endometrial carcinogenesis model and on an in vitro model in human colorectal cells[J].Mutat Res,2001,480-481 (4):201-207.
[12]Kumi DJ. Chemosensitivity of human prostate cancer cells PC3 and LNCaP to genistein isoflavone and beta-lapachone[J]. Biol Cell,2002,94(1):37-44.
[13]Hempstock J,Kavanagh JP,George NJ.Growth inhibition of prostate cell line in vitro by phyto-oestrogens[J].Br J Urol,1998,82(4):560-562.
[14]Lin X,Switzer BR,Demark WW. Effect of mammalian lignans on the growth of prostate cancer cell lines[J].Anticancer Res,2001,21(6):3995-3999.
[15]Rosenberg ZR,Jenkins DJ,Brown TJ,et al. Flavonoids can block PSA production by breast and prostate cancer cell lines[J].Clin Chim Acta,2002,317(1-2):17-26.
[16]Davis JN,Muqim N,Bhuiyan M,et al. Inhibition of prostate specific antigen expression by genistein in prostate cancer cells[J].Int J Oncol,2000,16(6):1091-1097.
[17]Shen JC,Klein RD,Wei Q,et al. Low-dose genistein induces cyclin dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells[J].Mol Carcinog,2000,29(2):92-102
[18]Zhou JR, Gugger ET, Tanaka T,et al. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis inmice[J]. J Nutr,1999,129 (9):1628-1635.
[19]Bylund A, Saarinen N, Zhang JX,et al. Anticancer effects of a plant lignan 7-hydroxymatairesinol on a prostate cancermodel in vivo[J]. Exp Biol Med (Maywood),2005, 230 (3):217-223.
[20]Pollard M, Wolter W. Prevention of spontaneous prostate-related cancer in Lobund-W istar rats by a soy protein isolate/isoflavone diet [J]. Prostate,2000,45(2):101-105.
[21]Wang J, Eltoum IE, Lamartiniere CA. Dietary genistein suppresses chemically induced prostate cancer in Lobund-Wistarrats[J].Cancer Lett,2002,186 (1):11-18.
[22]Mentor-Marcel R, Lamartiniere CA, Eltoum IE,et al. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenicmice (TRAMP) [J] Cancer Res,2001,61 (18):6777-6782.
[23]赵燕玲,潘子昂,王石麟,等.中国原发性骨质疏松症流行病学[J].中国骨质疏松杂志,2008,4(1)；218-219
[24]王洪复.骨质疏松诊断[J].国际内分泌代谢杂志,2006,26(4)：285-287
[25]Forbes AP, Fuller Albright. His concept of postmenopausal osteoporosis and what came of it[J].Clip Orthop Relat Res,1991,269(8):128-141
[26]崔新颖,张雪松.大豆异黄酮对实验大鼠骨质疏松症的影响[J].中国地方病防治杂志,2007,22(5)：370-371
[27]齐传芬,宋社吾,刘道芳,等.葛根异黄酮对去卵巢大鼠骨质疏松症的影响[J].生物学杂志,2007,24(1)：22-24
[28]冯英,涂平生,湛海伦,等.金雀异黄酮对去势大鼠骨质疏松的影响[J].中国骨质疏松杂志,2007,13(2)：105-107
[29]周延萌.红车抽草异黄酮对骨质疏松症的防治作用及机制研究[D].泰安.泰山医学院,2009：1-48
[30]张巧艳,秦路平,黄宝康,等.蛇床子总香豆素对去卵巢大鼠骨质疏松症的作用[J].中国药学杂志,2003,38(2)：101-103
[31]杨丽萍.蛇床子总香豆素对去卵粱大鼠骨质疏松症的作用[D].延吉.延边大学.2008：1-42
[32]赖远征,冯冰虹,刘美珍,等.补肾活血方对更年期大鼠性激素的影响[J].辽宁中医杂志,2004,31(1)：78-79
[33]郭建生,贺海波,王小娟,等.更年安神胶囊对去势雌性大鼠神经内分泌的影响[J].中医药学刊,2003,21(2)：262-264
[34]方肇勤,司富春,张伯呐,等.二仙汤及其拆方对老龄大鼠下丘脑GRnH基因转录与表达的调节作用[J].中国中医基础医学杂志,1998,4(1)：23-25
[35]张少文,张涛,谢文.补肾为主的中药复方对去卵巢大鼠性腺轴及甲状腺轴功能的影响[J].中国中医药科技,2003,10(2)：84-85
[36]刘忠厚.骨质疏松的研究与防治[M].北京.化学工业出版社,1994：80.
[37]蒙文斌,梁倍毓.补肾活血方对更年期大鼠FSH的影响[J].实验动物科学与管理,2005,22(2)：4-11
[38]戴雨,戴大江,河福金,等.4种中药提取物对去卵巢大鼠肝脏脂代谢影响机理研究[J].北京中医药大学学报,2002,25(6)：45-47
[39]步世忠,孙梅,张沉,等.更年健上调老年雌鼠下丘脑雌激素受体mRNA表达对P物质和p-内啡肤的影响[J].中国中西医结合杂志,1998,18(1)：28-31
[40]安胜军,李恩,赵京山.补肾方药对地塞米松所致实验性骨质疏松大鼠卵巢功能的影响[J].中国中西医结合杂志,2000,20(1)：46-49.
[41]陈东煌,等.补肾、健牌及脾肾双补对地塞米松诱发之骨质疏松大鼠PTH、CT、T、E2及BGP值影响的实验研究[J].实用骨科杂志,2002,8(2)：105-106.
[42]夏振信,等.补肾壮骨方抗骨质疏松的实验研究[J].中国中医骨伤科杂志,2002,10(6)：20-3.
[43]王建华,等.补肾方药对去卵巢大鼠骨密度及血清雌激素水平影响的实验研究[J].中国中医骨伤科杂志,2003,18(3)：6-7.
[44]黄艳红.补肾中药片对围绝经妇女骨质疏松代谢的影响[J].中国骨质疏松杂志,1993,13(9)：522-524.
[45]魏美娟.补肾药对雄性激素致无排卵大鼠垂体及卵巢的形态学变化观察[J].中国中西医结合杂志,1993,13(3)：164-166.
[46]范红霞,万力生,黎烈荣.更年安怡片治疗更年期综合征的临床与实验研究[J].中医药研究,1999,15(4)：45-49
[47]王滨,刘宏艳,王红.更年乐对更年期综合征网络机制影响的实验研究[J].江苏中医药.2002,23(10)：56
[48]陈芝喜,刘庆思,魏合伟.补肾活血药对去势雌鼠血清IL-2和激素水平的影响[J].放射免疫学杂志,2001,14(1)：13-16
[49]阴健,郭力工主编.中药现代研究与临床应用[M].北京.学苑出版社,1993：10-27
[50]李青南,等.淫羊藿提取液对去睾丸大鼠骨代谢的影响[J].中草药,1993,24(12)：637
[51]董晓萍,等.毛淫羊藿化学成分的研究[J].中国中医药杂志,1994,19(10)：61
[52]金秀莲,等.肉苁蓉化学成分研究进展[J].中国中医药杂志,1994,19(1)：695
[53]李美珠,等.虫草鸡精的药理研究[J].中成药,1992,14(10)：31
[54]刘人树.补骨脂的药理研究进展[J].中医药信息,1992,3(2)：15
[55]林瑞民,王大为,熊志立,等.补骨脂中两个黄酮类成分的高效液相色谱测定[J].中国中药杂志,2002,27(9)：669-671
[56]戴寿芝,等.构杞和构杞多糖与抗衰延寿[J].中国老年医学杂志,1994,1(6)：33
[57]吴赛珠主编.性激素平衡紊乱与疾病[M].北京.人民军医出版社.2005：45
[1].McKenna NJ,Lanz RB,O'Malley BW.Nuclear receptor coregulators:cellular and molecular biology[J].EndocrRev,1999,20(6):321-344.
[2].Hudelist QCzerwenka K,Kubista E,et al.Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue:AIB1 is a carcinoma-specific co-activator[J].Breast Cancer Res Treat,2003,78(3):193-204.
[3].Li J,O'Malley BW,Wong J,et al.p300 requires its histone acetyltransferase activity and SRC-1 interaction domain to facilitate thyroid hormone receptor activation in chromatin[J]. Mol Cell Biol,2000,20(4):2031-2042.
[4].Spencer TE, Jenster G, Burcin MM, et al.Steroid receptor coactivator-1 is a histone acetyltransferase[J].Nature.1997,389(2):194-198.
[5].Yang WM,Yao,YL,Sun,JM,et al.Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family [J]. J Biol Chem,1997,272(8):28001-28007.
[6].Lemon B, Tjian R.Orchestrated response:a symphony of transcription factors for gene control[J].Genes Dev,2000,14(4):2551-2569.
[7].Glass CK, Rosenfeld MG.The coregulator exchange in transcriptional functions of nuclear receptors[J].Genes Dev,2000,14(5):121-141.
[8].Fu M,Rao M,Wang C,et al.Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth[J].Mol Cell Biol,2003,23(2):8563-8575.
[9].Wang LG,Liu XM,Kreis W,et al.Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity [J]. Biochem-Biophys-Res-Commun,1999,259(5):21-28.
[10].Xu W,Cho H,Evans RM,et al.Acetylation and methylation in nuclear receptor gene activation[J].Methods Enzymol,2003,364(7):205-212.
[11].Li P, Yu X, Ge K, et al.Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer[J].Am J Pathol,2002,161(3):1467-1474.
[12].Mestayer C,Blanchere M,Jaubert F,et al.Expression of androgen receptor coactivators in normal and cancer prostate tissues and cultured cell lines[J].Prostate,2003,56(2):192-200.
[13].Fujimoto N,Mizokami A,Harada S,et al.Different expression of androgen receptor coactivators in human prostate[J].Urology,2001,58(3):289-294.
[14].Gregory CW,He B,Johnson RT,et al.A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy [J]. Cancer Res 2001,61(6):4315-4319.
[15].Lavinsky RM, Jepsen K, Heinzel T,et al.Diverse signaling pathways modulate nuclear receptor recruitment of NCoR and SMRT complexes[J]. Proc Natl Acad Sci, 1998,95(7):2920-2925.
[16].David Masiello,Shinta Cheng,Glenn J,et al.Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor [J]. J Biol Chem,2002,277(2):26321-26326.
[17].Bevan CL, Hoare S, Claessens F, et al.The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRCl[J].Mol Cell Biol,1999,19(7):8383-8392.
[18].Gregory CW, Hamil KG, Kim D, et, al. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgcn-regulated genes [J]. Cancer Res,1998,58(4):5718-5724.
[19].Ueda T,Bruchovsky N,Sadar MD,et al.Activation of androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways[J].J Biol,2002,277(9):7076-7085.
[20].Heinzel T, Lavinsky RM, Mullen TM, et al.A complex containig N-CoR, mSin3 and histone deacetylase mediates transcriptional repression[J].Nature,1997,387(5):43-48.
[21].Guoqing Liao,LiuhYow Chen,Aihua Zhang,et al.Regulation of Androgen Receptor Activity by the Nuclear Receptor Corepressor SMRT[J]J Biol Chem,2003,278(4):5052-5061.
[22].Yu X,Li P,Roeder RG,et al.Inhibition of androgen receptor-mediated transcription by amino-terminal enhancer of split[J].Mol Cell Biol,2001,21(6):4614-4625.
[23].Huang ZhiQing, Li Jiwen, Wong JieMin, et al.AR possesses an intrinsic hormone independent transcriptional activity[J].Mol Endocrinol,2002,16(2):924-937.
[24].Shinta Cheng, Sabrina Brzostek, Suzanne R, et al. Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor ressor [J]. Mol Endocrinol.2002,16 (6):1492-1501.
[25].Heinz-Joachim List, Catharine L, Smith,et al.Inhibition of histone deacetylation augments dihydrotestosterone induction of androgen receptor levels:an explanation for trichostatin A effects on androgen-induced chromatin remodeling and transcription of the mouse mammary tumor virus promoter[J].Exp Cell Res,1999,25(9)2:471-478.
[26].Pich A, Chiusa L, Margaria E.Prognostic relevance of AgNORs in tumor pathology[J]. Micron.2000,2(5):133-141
[27].Heery DM, Kalkhoven E, Hoare S, et al.A signature motif in transcriptional co-activators mediates binding to nuclear receptors[J].Nature,1997,387(3):733-736.
[28].Torchia J, Rose DW, Inostroza J, et al.The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function[J].Nature,1997,387(2):677-684.
[29].Feng W,Ribeiro RC,Wagner RL,et al.Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors[J].Science,1998,280(6):1747-1749.
[30].Shiau AK,Barstad D,Loria PM,et al.The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen[J].Cell,1998,95(3):927-937.
[31].Hu X, Lazar MA.The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors[J].Nature,1999,402(4):93-96.
[32].Perissi V,Staszewski LM,McInerney EM,et al.Molecular determinants of nuclear receptor corepressor interaction[J].Genes Dev,1999,13(7):3198-3208.
[33].Nagy L,Kao HY,Love JD,et al.Mechanism of corepressor binding and release from nuclear hormone receptors[J].Genes Dev,1999,13(5):3209-3216.
[34].Webb P,Anderson CM,Valentine C,et al.The nuclear receptor corepressor(NCoR) contains three isoleucine motifs(I/LXXII)that serve as receptor interaction domains (IDs) [J].Mol Endocrinol,2000,14(2):1976-1985.
[35].Cohen RN, Putney A, Wondisford FE, et al.The nuclear corepressors recognize distinct nuclear receptor complexes[J].Mol Endocrinol,2000,14(3):900-914.
[36].Cohen RN, Brzostek S, Kim B, et, al. The specificity of interactions between nuclear hormone receptors and corepressors is mediated by distinct amino acid sequences within the interacting domains[J].Mol Endocrinol,2001,15(l):1049-1061.
[37].Kyprianou N, English HF, Isaacs JT.Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation[J].Cancer Res,1990,50(7):3748-3753.
[38].Gregory CW, Hamil KG, Kim D, et al.Androgen receptor expression in androgen-independent prostate canceris associated with increased expression of androgen-regulated genes [J]. Cancer Res,1998,58(6):5718-5724.
[39].Edwards J,Krishna NS,Grigor KM,et al.Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer[J].Br J Cancer,2003,89(1):552-556.
[40].Lee LF, Guan J, Qiu Y, et al.Neuropeptide-induced androgen independence in prostate cancer cells:roles of nonreceptor tyrosine kinases Etk/Bmx[J].Srol,2001,21(7):8385-97.
[41].Gregory CW,Johnson RT,Mohler JL,et al.Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen[J].Cancer Res,2001, 61(8):2892-2898.
[42].Culig Z, Hoffmann J, Erdel M, et al.Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system[J].Br J Cancer,199981(6):242-251.
[43].Schuurmans AL, Bolt J, Voorhorst MM, et al.Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids[J].Int J Cancer,1988,42(4):917-922.
[44].江军,王洛夫,方玉华,等.雄激素受体反义RNA对前列腺癌细胞雄激素受体表达的抑制用的研究[J].第三军医大学学报,2003,25(9)：501-504.
[45].Pollack A,Cowen D,Troncoso P,et al.Molecular markers of outcome after radiotherapy in patients with prostate carcinoma:Ki-67,bcl-2,bax,and bcl-x[J].Cancer.2003,7(6):1630-1638
[46].Sulik M, Guzinska-Ustymowicz K.Expression of Ki-67 and PCNA as proliferating markers in prostate cancer[J].Rocz-Akad-Med-Bialymst.2002,47(8):262-269
[47].Banerjee Partha-P, Banerjee Subhadra.Bcl-2 protein expression correlates with cell survival and androgen independence in rat prostatic lobes[J]. Endocrinology.2002; 5(3):1825-1832
[48].Szostak MJ, Kaur P, Amin P, et al.Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy[J]J-Urol.2001,6(5):2126-2130
[49].Bruckheimer EM, Brisbay S, Johnson DJ,et al.Bcl-2 accelerates multistep prostate carcinogenesis in vivo[J].Oncogene.200046(8):5251-5258
[50].Lowe SL, Rubinchik S, Honda T, et al.Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNcap prostate cancer cells [J]. Gene-Ther.2001,18 (4):1363-1371
[51].Perlman H, Zhang X, Chen MW, et al.An elevated bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis[J]. Cell-Death-Differ.1999, 1(2):48-54
[52].Mackey TJ,Borkowski A,Amin P,et al.Jacobs bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer[J]. Urology. 1998,6(5):1085-1090
[53].顾方六主编.现代前列腺病学[M].人民军医出版社,2002年1月
[54].Pollack A,Cowen D,Troncoso P,et al.Molecular markers of outcome after radiotherapy in patients with prostate carcinoma:Ki-67,bcl-2,bax,and bcl-x[J].Cancer.2003,7(3):1630-1638
[2]Gao X,Loggie B W,Nawaz Z. The roles of sex steroid receptor coregulators in cancer[J]. Mol Cancer,2004,14(5):1-7.
[3]Smith C L,O'Malley B W. Coregulator function:a key to under-standing tissue specificity of selective receptor modulators[J]. Endo Rev,2004,25(6):45-71.
[4]Dehm S M,Tindall D J. Androgen receptor structural and functional elements:role and regulation in prostate cancer[J]. Mol Endocrinol,2007,21(3):2855-2863.
[5]Brinkmann AO. Molecular basis of androgen insensitivity [J]. Mol Cell Endocrinol, 2001,179(9):105-109.
[6]Culig Z,Klocker H,Bartsch G,et al. Androgen receptor in prostate cancer[J]. J Urol,2003, 170(5):1363-1369.
[7]M E Taplin, S P Balk. Androgen receptor:a key molecule in the progression of prostate cancer to hormone independence[J].Journal of Cellular Biochemistry,2004,91(7):483-490.
[8]O.Sartor,Q.Zheng,J.A.Eastham,Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer[J].Urology,1999,53(4):378-380.
[9]E Giovannucci,M J Stampfer,K Krithivas.The CAG repeat within the androgen receptor gene and its relationship to prostate cancer[J].Proceedings of the National Academy of Sciences of the United States of America,1997,94(7):3320-3323.
[10]D O Hardy,H I Scher,T Bogenreider.Androgen receptor CAG repeat lengths in prostate cancer:correlation with age of onset[J].The Journal of Clinical Endocrinology and Metabolism,1996,81(9):4400-4405.
[11]R K Nam,Y Elhaji, M D Krahn.Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression[J].The Journal of Urology,2000, 164(3):567-572.
[12]A Haelens, T Tanner, S Denayer.The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor [J]. Cancer Research, 2007,67(6):4514-4523.
[13]E P Gelmann.Molecular biology of the androgen receptor[J] Journal of Clinical Oncology,2002,20(7):3001-3015.
[14]P J Kallio, J J Palvimo, M Mehto.Analysis of androgen receptor-DNA interactions with receptor proteins produced in insect cells[J].The Journal of Biological Chemistry, 1994,269(4):11514-11522.
[15]CA Berrevoets, A Umar, A O Brinkmann.Antiandrogens:selective androgen receptor modulators [J].Molecular and Cellular Endocrinology,2002,198(3):97-103.
[16]Y Shang, M Myers, M Brown.Formation of the androgen receptor transcription complex [J].Molecular Cell,2002,9(1):601-610.
[17]M.C.Louie,H.Q.Yang,A.H.Ma.Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex [J].Proceedings of the National Academy of Sciences of the United States of America,2003,100(6):2226-2230.
[18]XB Shi,L Xue,J Yang.An androgen-regulated miRNA suppresses Bakl expression and induces androgen-independent growth of prostate cancer cells[J].Proceedings of the National Academy of Sciences of the United States of America,2007,104(3):19983-19988.
[19]C.A.Berrevoets, A.Umar, A O Brinkmann. Antiandrogens:selective androgen receptor modulators [J].Molecular and Cellular Endocrinology,2002,198(7):97-103.
[20]Edwards J,Krishna N S,Grigor K M,et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer[J]. Br J Cancer,2003,89(4):552-526.
[21]Culig Z,Hobisch A,Cronauer M V,et al. Regulation of prostatic growth and function by peptide growth factors[J]. Prostate,1996,28(2):392-405.
[22]Tan J,Sharief Y,Hamil K G,et al. Dehydroepiandrosterone acti-vates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells[J]. Mol Endocrinol,1997,11(4):450-459.
[23]Park J J,Irvine R A,Buchanan G,et al. Breast cancer susceptibility gene l(BRCAl)is a coactivator of the androgen receptor[J]. Cancer Res,2000,60(6):5946.
[24]Gao X,Loggie B W,Nawaz Z. The roles of sex steroid receptor coregulators in cancer[J]. Mol Cancer,2004,14(4):1-7.
[25]Smith C L,O'Malley B W. Coregulator function:a key to under-standing tissue specificity of selective receptor modulators[J]. Endo Rev,2004,25(4):45-71.
[26]Fu M,Rao M,Wang C,et al.Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth[J].Mol Cell Biol,2003,23(3):8563-8575.
[27]Berrevoets P, Doesburg K, Steketee J, et al.Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2(transcriptional intermediary factor) [J]. Mol Endocrinol, 1998,12(3):1172-1183.
[28]Wang G,Liu XM,Kreis W,et al.Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity[J].Biochem Biophys Res Commun,1999,259(4):21-28.
[29]Xu W,Cho H,Evans RM,et al.Acetylation and methylation in nuclear receptor gene activation[J].Methods Enzymol,2003,364(2):205-212.
[30]Culig Z,Klocker H,Bartsch G,et al.Androgen receptor mutations in carcinoma of the prostate:significance for endocrine therapy[J].Am J Pharmacogenomics,2001,1(6):241-9.
[31]Gao X,Loggie B W,Nawaz Z. The roles of sex steroid receptor coregulators in cancer[J]. Mol Cancer,2004,14(5):1-7.
[32]Smith C L,O'Malley B W. Coregulator function:a key to understanding tissue specificity of selective receptor modulators[J]. Endo Rev,2004,25(5):45-71.
[33]Chang C Y,McDonnell D P. Androgen-receptor-cofactor interactions as targets for drug discovery[J]. Trends Pharmacol Sci,2005,26(1):225-228.
[34]Xu J,Qiu Y,DeMayo F J,et al. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1)gene[J]. Science,1998,279(7):1922-1925.
[35]Tanaka Y,Naruse I,Hongo T,et al. Extensive brain hemorrhage and embryonic lethality in a mouse null mutant of CREB-binding protein[J]. Mech Dev,2000,95(6):133-145.
[36]Yao T P,Oh S P,Fuchs M,et al. Gene-dosage dependent embry-onic development and proliferation defects in mice lacking the transcriptional integrator p300[J]. Cell, 1998,93(4):361-372.
[37]Heemers H V,Tindall D J. Androgen receptor(AR)coregulators:a diversity of functions converging on and regulating the AR transcriptional complex[J]. Endo Rev,2007,28(2):778-808.
[38]Chen H,Lin R J,Schiltz R L,et al.Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300[J]. Cell,1997,90(3):569-580.
[39]Stallcup M R,Kim J H,Teyssier C,et al.The roles of protein-protein interactions and protein methylation in transcriptional acti-vation by nuclear receptors and their coactivators. Steroid Biochem[J]. Mol Biol,2003,85(2-5):139-145.
[40]Chen C D,Welsbie D S,Tran C,et al.Molecular determinants of resistance to antiandrogen therapy[J].NatMed,2004,10(5):33-39.
[41]Gregory C W,He B,Johnson R T,et al.A mechanism for andro-gen receptor-mediated prostate cancer recurrence after androgen de-privation therapy [J]. Cancer Res,2001, 61(3):4315-4319.
[42]Zhou H J, Yan J, Luo W,et al.SRC-3 is required for prostate cancer cell proliferation and survival[J].CancerRes,2005,65(7):7976-7983.
[43]Chen H,Lin RJ,Schiltz RL,et al.Nuclear receptor co-activator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with p/CAF and CBPIp300[J].Cell,1997,90(6):569-580.
[44]Li H,Gomes PJ,Chen JD,et al.AC3,a steroid/nuclear receptor associated coactivator that is related to SRC-1 and TIF2[J].Proc Nat/Acad Sci,1997,94(4):6479-8464.
[45]Takeshita A, Cardona GR, Koibuchi N, et val.a novel 1 BO-kDa thvroid hormone receotor activator molecule:exhibits distinct pioperties from steroid receptor co-activator-1[J].J Biol Chem,1997,272(5):27629-27634.
[46]Taneja S S,Ha S,Swenson N K,et al.ART-27,an androgen re-ceptor coactivator regulated in prostate development and cancer[J].J Biol Chem,2004,279(14):13944-13952.
[47]Yeh S, Chang C.Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells [J].Proc Natl Acad Sci USA,1996,93(9):5517-5521.
[48]Sampson ER, Yeh SY, Chang HC, et al.Identification and characterization of androgen receptor associated coregulators in prostate cancer cells[J].J Biol Regul Homeost Agents,2001,15(8):123-129.
[49]Wang Xin,Yang Yue,Guo Xiaojian,et al.Suppression of androgen receptor transactivation by Pyk2 via interaction and phosphorylation of the ARA55 coregulator[J]J Biol Chem,2002,277(7):15426-15431.
[50]Kang HY,Yeh S,Fujimoto N,et al.Cloning and characterization of human prostate coactivator ARA54,a novel protein that associates with the androgen receptor[J].J Biol Chem,1999,274(3):8570-8576.
[51]Hsiao PW,Lin DL,Nakao R,et al.The linkage of Kennedy's neuron disease to ARA24,the first identified androgen receptor polyglutamine region-associated coactivator[J].J Biol Chem,1999,274(2):20229-20234.
[52]Yeh S,Sampson ER,Lee DK,et al.Functional analysis of androgen receptor N-terminal and ligand binding domain interacting coregulators in prostate cancer[J].J Formos Med Assoc,2000,99(6):885-894.
[53]Hsiao PW,Chang C.Isolation and characterization of ARA160 as the first androgen receptor N-terminal-associated coactivator in human prostate cells[J]J Biol Chem,1999,274(5):22373-22379.
[54]Miyamoto H,Rahman M M,Chang C.Molecular basis for the antiandrogen withdrawal syndrome[J].J Cell Biochem,2004,91(1):3-12.
[55]Huang ZhiQing, Li Jiwen, Wong Jiemin, et al.AR possesses an intrinsic hormone-independent transcriptional activity[J].Mol-Endocrinol,2002,16(4):924-3733.
[56]Heinzel T, Lavinsky RM, Mullen TM, et al.A complex containig N-CoR, mSin3 and histone deacetylase mediates transcriptional repression[J].Nature,1997,387(7):43-48.
[57]Cheng S,Brzostek S,Lee SR,et al.Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor[J].Mol-Endocrinol,2002,16(4):1492-1501.
[58]Guoqing Liao,LiuhYow Chen,Aihua Zhang,et al.Regulation of Androgen Receptor Activity by the Nuclear Receptor Corepressor SMRT[J].J Biol Chem,2003,278(2):5052-5061.
[59]Hu X, Lazar MA.The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors[J].Nature,1999,402(5):93-96.
[60]Perissi V,Staszewski LM,McInerney EM,et al.Molecular of nuclear determinants receptor corepressor interaction[J].Genes Dev,1999,13(8):3198-3208.
[61]Nagy L,Kao HY,Love JD,et al.Mechanism of corepressor binding and release from nuclear hormone receptors[J].Genes Dev,1999,13(4):3209-3216.
[62]Xu HE, Stanley TB, Montana VG,et al.Structural basis for antagonist mediated recruitment of nuclear co-repressors by PPARalpha[J].Nature,2002,415(1):813-817.
[63]Ghosh JC,Yang X,Zhang A,et al.Interactions that determine the assembly of a retinoid X receptor/corepressor complex[J].Proc Natl Acad Sci,2002 99(7):5842-5847.
[64]Dotzlaw Helmut, Moehren Udo, Mink Sigrun, et al.Theamino terminus of the human AR is target for corepressor action and antihormone agonism [J]. Mol-Endocrinol, 2002,16(3):661-673.
[65]Fujimoto N,Mizokami A,Harada S,et al.Different expression of androgen receptor coactivators in human prostate[J].Urology,2001,58(9):289-294.
[66]Gregory CW,He B,Johnson RT,et al.A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy [J]. Cancer Res,2001, 61(7):4315-4319.
[67]Osborne CK,Bardou V,Hopp TA,et al.Role of the estrogen receptor coactivator AIBl(SRC-3)and HER-2/neu in tamoxifen resistance in breast cancer[J]J Natl Cancer Inst,2003,95(7):353-361.
[1]史轶蘩主编.协和内分泌和代谢学.北京.科学技术出版社[M].1999：52
[2]白晓霞.植物雌激素与传统的激素替代疗法[J].国外医学妇幼保健分册,2002,13(3)：113-115
[3]Zava DT,Duwe GEstrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro[J].Nutr Cancer,1997,27(1):31-40.
[4]贺红莉,金焕,王继峰,等.雌激素受体调节剂及其相关中药的研究进展[J].中国中药杂志,2002,27(11)：805-807.
[5]Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women; principal resuts From the Women, Health Initiative randomized controlled trial[J].JAMA,2002,288(3);321-333
[6]Albright F. Postmenopausal Osteoporosis[J]. Traps Assoc Amphysic,71940,55(7); 298
[7]孔令娜,左萍萍,植物雌激素研究进展[J].生殖医学杂志,2003,12(1)；46-53
[8]Sakamoto T,Horiguchi H,Oguma E,et al.Effects of diverse dietary phytoestrogens on cell growth,cell cycle and apoptosis in estrogen-receptor-positive breast cancer cells[J].Nutr Biochem,2010,21 (9):856-864.
[9]Lamartiniere CA. Protection against breast cancerwith genistein:acomponent of soy[J].Am J Clin Nutr,2000,717(2):1705-1707.
[10]Galluzzo P, Martini C, Bulzomi P, et al.Quercetin-induced apoptotic cascade in cancer cells:antioxidant versus estrogen receptor alpha-dependent mechanisms[J].Mol Nutr Food Res> 2009,53 (6):699-708.
[11]Mori H, Niwa K, Zheng Q, et al.Cell proliferation in cancer prevention;effects of preventive agents on estrogen-related endometrial carcinogenesis model and on an in vitro model in human colorectal cells[J].Mutat Res,2001,480-481 (4):201-207.
[12]Kumi DJ. Chemosensitivity of human prostate cancer cells PC3 and LNCaP to genistein isoflavone and beta-lapachone[J]. Biol Cell,2002,94(1):37-44.
[13]Hempstock J,Kavanagh JP,George NJ.Growth inhibition of prostate cell line in vitro by phyto-oestrogens[J].Br J Urol,1998,82(4):560-562.
[14]Lin X,Switzer BR,Demark WW. Effect of mammalian lignans on the growth of prostate cancer cell lines[J].Anticancer Res,2001,21(6):3995-3999.
[15]Rosenberg ZR,Jenkins DJ,Brown TJ,et al. Flavonoids can block PSA production by breast and prostate cancer cell lines[J].Clin Chim Acta,2002,317(1-2):17-26.
[16]Davis JN,Muqim N,Bhuiyan M,et al. Inhibition of prostate specific antigen expression by genistein in prostate cancer cells[J].Int J Oncol,2000,16(6):1091-1097.
[17]Shen JC,Klein RD,Wei Q,et al. Low-dose genistein induces cyclin dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells[J].Mol Carcinog,2000,29(2):92-102
[18]Zhou JR, Gugger ET, Tanaka T,et al. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis inmice[J]. J Nutr,1999,129 (9):1628-1635.
[19]Bylund A, Saarinen N, Zhang JX,et al. Anticancer effects of a plant lignan 7-hydroxymatairesinol on a prostate cancermodel in vivo[J]. Exp Biol Med (Maywood),2005, 230 (3):217-223.
[20]Pollard M, Wolter W. Prevention of spontaneous prostate-related cancer in Lobund-W istar rats by a soy protein isolate/isoflavone diet [J]. Prostate,2000,45(2):101-105.
[21]Wang J, Eltoum IE, Lamartiniere CA. Dietary genistein suppresses chemically induced prostate cancer in Lobund-Wistarrats[J].Cancer Lett,2002,186 (1):11-18.
[22]Mentor-Marcel R, Lamartiniere CA, Eltoum IE,et al. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenicmice (TRAMP) [J] Cancer Res,2001,61 (18):6777-6782.
[23]赵燕玲,潘子昂,王石麟,等.中国原发性骨质疏松症流行病学[J].中国骨质疏松杂志,2008,4(1)；218-219
[24]王洪复.骨质疏松诊断[J].国际内分泌代谢杂志,2006,26(4)：285-287
[25]Forbes AP, Fuller Albright. His concept of postmenopausal osteoporosis and what came of it[J].Clip Orthop Relat Res,1991,269(8):128-141
[26]崔新颖,张雪松.大豆异黄酮对实验大鼠骨质疏松症的影响[J].中国地方病防治杂志,2007,22(5)：370-371
[27]齐传芬,宋社吾,刘道芳,等.葛根异黄酮对去卵巢大鼠骨质疏松症的影响[J].生物学杂志,2007,24(1)：22-24
[28]冯英,涂平生,湛海伦,等.金雀异黄酮对去势大鼠骨质疏松的影响[J].中国骨质疏松杂志,2007,13(2)：105-107
[29]周延萌.红车抽草异黄酮对骨质疏松症的防治作用及机制研究[D].泰安.泰山医学院,2009：1-48
[30]张巧艳,秦路平,黄宝康,等.蛇床子总香豆素对去卵巢大鼠骨质疏松症的作用[J].中国药学杂志,2003,38(2)：101-103
[31]杨丽萍.蛇床子总香豆素对去卵粱大鼠骨质疏松症的作用[D].延吉.延边大学.2008：1-42
[32]赖远征,冯冰虹,刘美珍,等.补肾活血方对更年期大鼠性激素的影响[J].辽宁中医杂志,2004,31(1)：78-79
[33]郭建生,贺海波,王小娟,等.更年安神胶囊对去势雌性大鼠神经内分泌的影响[J].中医药学刊,2003,21(2)：262-264
[34]方肇勤,司富春,张伯呐,等.二仙汤及其拆方对老龄大鼠下丘脑GRnH基因转录与表达的调节作用[J].中国中医基础医学杂志,1998,4(1)：23-25
[35]张少文,张涛,谢文.补肾为主的中药复方对去卵巢大鼠性腺轴及甲状腺轴功能的影响[J].中国中医药科技,2003,10(2)：84-85
[36]刘忠厚.骨质疏松的研究与防治[M].北京.化学工业出版社,1994：80.
[37]蒙文斌,梁倍毓.补肾活血方对更年期大鼠FSH的影响[J].实验动物科学与管理,2005,22(2)：4-11
[38]戴雨,戴大江,河福金,等.4种中药提取物对去卵巢大鼠肝脏脂代谢影响机理研究[J].北京中医药大学学报,2002,25(6)：45-47
[39]步世忠,孙梅,张沉,等.更年健上调老年雌鼠下丘脑雌激素受体mRNA表达对P物质和p-内啡肤的影响[J].中国中西医结合杂志,1998,18(1)：28-31
[40]安胜军,李恩,赵京山.补肾方药对地塞米松所致实验性骨质疏松大鼠卵巢功能的影响[J].中国中西医结合杂志,2000,20(1)：46-49.
[41]陈东煌,等.补肾、健牌及脾肾双补对地塞米松诱发之骨质疏松大鼠PTH、CT、T、E2及BGP值影响的实验研究[J].实用骨科杂志,2002,8(2)：105-106.
[42]夏振信,等.补肾壮骨方抗骨质疏松的实验研究[J].中国中医骨伤科杂志,2002,10(6)：20-3.
[43]王建华,等.补肾方药对去卵巢大鼠骨密度及血清雌激素水平影响的实验研究[J].中国中医骨伤科杂志,2003,18(3)：6-7.
[44]黄艳红.补肾中药片对围绝经妇女骨质疏松代谢的影响[J].中国骨质疏松杂志,1993,13(9)：522-524.
[45]魏美娟.补肾药对雄性激素致无排卵大鼠垂体及卵巢的形态学变化观察[J].中国中西医结合杂志,1993,13(3)：164-166.
[46]范红霞,万力生,黎烈荣.更年安怡片治疗更年期综合征的临床与实验研究[J].中医药研究,1999,15(4)：45-49
[47]王滨,刘宏艳,王红.更年乐对更年期综合征网络机制影响的实验研究[J].江苏中医药.2002,23(10)：56
[48]陈芝喜,刘庆思,魏合伟.补肾活血药对去势雌鼠血清IL-2和激素水平的影响[J].放射免疫学杂志,2001,14(1)：13-16
[49]阴健,郭力工主编.中药现代研究与临床应用[M].北京.学苑出版社,1993：10-27
[50]李青南,等.淫羊藿提取液对去睾丸大鼠骨代谢的影响[J].中草药,1993,24(12)：637
[51]董晓萍,等.毛淫羊藿化学成分的研究[J].中国中医药杂志,1994,19(10)：61
[52]金秀莲,等.肉苁蓉化学成分研究进展[J].中国中医药杂志,1994,19(1)：695
[53]李美珠,等.虫草鸡精的药理研究[J].中成药,1992,14(10)：31
[54]刘人树.补骨脂的药理研究进展[J].中医药信息,1992,3(2)：15
[55]林瑞民,王大为,熊志立,等.补骨脂中两个黄酮类成分的高效液相色谱测定[J].中国中药杂志,2002,27(9)：669-671
[56]戴寿芝,等.构杞和构杞多糖与抗衰延寿[J].中国老年医学杂志,1994,1(6)：33
[57]吴赛珠主编.性激素平衡紊乱与疾病[M].北京.人民军医出版社.2005：45
[1].McKenna NJ,Lanz RB,O'Malley BW.Nuclear receptor coregulators:cellular and molecular biology[J].EndocrRev,1999,20(6):321-344.
[2].Hudelist QCzerwenka K,Kubista E,et al.Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue:AIB1 is a carcinoma-specific co-activator[J].Breast Cancer Res Treat,2003,78(3):193-204.
[3].Li J,O'Malley BW,Wong J,et al.p300 requires its histone acetyltransferase activity and SRC-1 interaction domain to facilitate thyroid hormone receptor activation in chromatin[J]. Mol Cell Biol,2000,20(4):2031-2042.
[4].Spencer TE, Jenster G, Burcin MM, et al.Steroid receptor coactivator-1 is a histone acetyltransferase[J].Nature.1997,389(2):194-198.
[5].Yang WM,Yao,YL,Sun,JM,et al.Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family [J]. J Biol Chem,1997,272(8):28001-28007.
[6].Lemon B, Tjian R.Orchestrated response:a symphony of transcription factors for gene control[J].Genes Dev,2000,14(4):2551-2569.
[7].Glass CK, Rosenfeld MG.The coregulator exchange in transcriptional functions of nuclear receptors[J].Genes Dev,2000,14(5):121-141.
[8].Fu M,Rao M,Wang C,et al.Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth[J].Mol Cell Biol,2003,23(2):8563-8575.
[9].Wang LG,Liu XM,Kreis W,et al.Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity [J]. Biochem-Biophys-Res-Commun,1999,259(5):21-28.
[10].Xu W,Cho H,Evans RM,et al.Acetylation and methylation in nuclear receptor gene activation[J].Methods Enzymol,2003,364(7):205-212.
[11].Li P, Yu X, Ge K, et al.Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer[J].Am J Pathol,2002,161(3):1467-1474.
[12].Mestayer C,Blanchere M,Jaubert F,et al.Expression of androgen receptor coactivators in normal and cancer prostate tissues and cultured cell lines[J].Prostate,2003,56(2):192-200.
[13].Fujimoto N,Mizokami A,Harada S,et al.Different expression of androgen receptor coactivators in human prostate[J].Urology,2001,58(3):289-294.
[14].Gregory CW,He B,Johnson RT,et al.A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy [J]. Cancer Res 2001,61(6):4315-4319.
[15].Lavinsky RM, Jepsen K, Heinzel T,et al.Diverse signaling pathways modulate nuclear receptor recruitment of NCoR and SMRT complexes[J]. Proc Natl Acad Sci, 1998,95(7):2920-2925.
[16].David Masiello,Shinta Cheng,Glenn J,et al.Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor [J]. J Biol Chem,2002,277(2):26321-26326.
[17].Bevan CL, Hoare S, Claessens F, et al.The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRCl[J].Mol Cell Biol,1999,19(7):8383-8392.
[18].Gregory CW, Hamil KG, Kim D, et, al. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgcn-regulated genes [J]. Cancer Res,1998,58(4):5718-5724.
[19].Ueda T,Bruchovsky N,Sadar MD,et al.Activation of androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways[J].J Biol,2002,277(9):7076-7085.
[20].Heinzel T, Lavinsky RM, Mullen TM, et al.A complex containig N-CoR, mSin3 and histone deacetylase mediates transcriptional repression[J].Nature,1997,387(5):43-48.
[21].Guoqing Liao,LiuhYow Chen,Aihua Zhang,et al.Regulation of Androgen Receptor Activity by the Nuclear Receptor Corepressor SMRT[J]J Biol Chem,2003,278(4):5052-5061.
[22].Yu X,Li P,Roeder RG,et al.Inhibition of androgen receptor-mediated transcription by amino-terminal enhancer of split[J].Mol Cell Biol,2001,21(6):4614-4625.
[23].Huang ZhiQing, Li Jiwen, Wong JieMin, et al.AR possesses an intrinsic hormone independent transcriptional activity[J].Mol Endocrinol,2002,16(2):924-937.
[24].Shinta Cheng, Sabrina Brzostek, Suzanne R, et al. Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor ressor [J]. Mol Endocrinol.2002,16 (6):1492-1501.
[25].Heinz-Joachim List, Catharine L, Smith,et al.Inhibition of histone deacetylation augments dihydrotestosterone induction of androgen receptor levels:an explanation for trichostatin A effects on androgen-induced chromatin remodeling and transcription of the mouse mammary tumor virus promoter[J].Exp Cell Res,1999,25(9)2:471-478.
[26].Pich A, Chiusa L, Margaria E.Prognostic relevance of AgNORs in tumor pathology[J]. Micron.2000,2(5):133-141
[27].Heery DM, Kalkhoven E, Hoare S, et al.A signature motif in transcriptional co-activators mediates binding to nuclear receptors[J].Nature,1997,387(3):733-736.
[28].Torchia J, Rose DW, Inostroza J, et al.The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function[J].Nature,1997,387(2):677-684.
[29].Feng W,Ribeiro RC,Wagner RL,et al.Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors[J].Science,1998,280(6):1747-1749.
[30].Shiau AK,Barstad D,Loria PM,et al.The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen[J].Cell,1998,95(3):927-937.
[31].Hu X, Lazar MA.The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors[J].Nature,1999,402(4):93-96.
[32].Perissi V,Staszewski LM,McInerney EM,et al.Molecular determinants of nuclear receptor corepressor interaction[J].Genes Dev,1999,13(7):3198-3208.
[33].Nagy L,Kao HY,Love JD,et al.Mechanism of corepressor binding and release from nuclear hormone receptors[J].Genes Dev,1999,13(5):3209-3216.
[34].Webb P,Anderson CM,Valentine C,et al.The nuclear receptor corepressor(NCoR) contains three isoleucine motifs(I/LXXII)that serve as receptor interaction domains (IDs) [J].Mol Endocrinol,2000,14(2):1976-1985.
[35].Cohen RN, Putney A, Wondisford FE, et al.The nuclear corepressors recognize distinct nuclear receptor complexes[J].Mol Endocrinol,2000,14(3):900-914.
[36].Cohen RN, Brzostek S, Kim B, et, al. The specificity of interactions between nuclear hormone receptors and corepressors is mediated by distinct amino acid sequences within the interacting domains[J].Mol Endocrinol,2001,15(l):1049-1061.
[37].Kyprianou N, English HF, Isaacs JT.Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation[J].Cancer Res,1990,50(7):3748-3753.
[38].Gregory CW, Hamil KG, Kim D, et al.Androgen receptor expression in androgen-independent prostate canceris associated with increased expression of androgen-regulated genes [J]. Cancer Res,1998,58(6):5718-5724.
[39].Edwards J,Krishna NS,Grigor KM,et al.Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer[J].Br J Cancer,2003,89(1):552-556.
[40].Lee LF, Guan J, Qiu Y, et al.Neuropeptide-induced androgen independence in prostate cancer cells:roles of nonreceptor tyrosine kinases Etk/Bmx[J].Srol,2001,21(7):8385-97.
[41].Gregory CW,Johnson RT,Mohler JL,et al.Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen[J].Cancer Res,2001, 61(8):2892-2898.
[42].Culig Z, Hoffmann J, Erdel M, et al.Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system[J].Br J Cancer,199981(6):242-251.
[43].Schuurmans AL, Bolt J, Voorhorst MM, et al.Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids[J].Int J Cancer,1988,42(4):917-922.
[44].江军,王洛夫,方玉华,等.雄激素受体反义RNA对前列腺癌细胞雄激素受体表达的抑制用的研究[J].第三军医大学学报,2003,25(9)：501-504.
[45].Pollack A,Cowen D,Troncoso P,et al.Molecular markers of outcome after radiotherapy in patients with prostate carcinoma:Ki-67,bcl-2,bax,and bcl-x[J].Cancer.2003,7(6):1630-1638
[46].Sulik M, Guzinska-Ustymowicz K.Expression of Ki-67 and PCNA as proliferating markers in prostate cancer[J].Rocz-Akad-Med-Bialymst.2002,47(8):262-269
[47].Banerjee Partha-P, Banerjee Subhadra.Bcl-2 protein expression correlates with cell survival and androgen independence in rat prostatic lobes[J]. Endocrinology.2002; 5(3):1825-1832
[48].Szostak MJ, Kaur P, Amin P, et al.Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy[J]J-Urol.2001,6(5):2126-2130
[49].Bruckheimer EM, Brisbay S, Johnson DJ,et al.Bcl-2 accelerates multistep prostate carcinogenesis in vivo[J].Oncogene.200046(8):5251-5258
[50].Lowe SL, Rubinchik S, Honda T, et al.Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNcap prostate cancer cells [J]. Gene-Ther.2001,18 (4):1363-1371
[51].Perlman H, Zhang X, Chen MW, et al.An elevated bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis[J]. Cell-Death-Differ.1999, 1(2):48-54
[52].Mackey TJ,Borkowski A,Amin P,et al.Jacobs bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer[J]. Urology. 1998,6(5):1085-1090
[53].顾方六主编.现代前列腺病学[M].人民军医出版社,2002年1月
[54].Pollack A,Cowen D,Troncoso P,et al.Molecular markers of outcome after radiotherapy in patients with prostate carcinoma:Ki-67,bcl-2,bax,and bcl-x[J].Cancer.2003,7(3):1630-1638